MAPT and Alzheimer disease: Indeed, various biomarkers in cerebrospinal fluid (CSF), such as Aβ42 and tau protein, have been explored with the purpose of using them for differential diagnosis between MCI, Alzheimer’s disease (AD), and cognitively normal subjects (Dunne et al., 2021; Papaliagkas et al., 2023).